Mark Johnson | Vice President of Investor Relations |
Steve Davis | Chief Executive Officer |
Brendan Teehan | Chief Operating Officer, Head of Commercial |
Doug Williamson | Head of Research & Development |
Mark Schneyer | Chief Financial Officer |
Kathie Bishop | Chief Scientific Officer and Head of Rare Diseases |
Ritu Baral | TD Cowen |
Charles Duncan | Cantor Fitzgerald |
Tessa Romero | J.P. Morgan |
Tazeen Ahmad | Bank of America |
Neena Bitritto-Garg | Citi |
Rudy Li | SVB Securities |
Gregory Renza | RBC Capital Markets |
Jason Butler | JMP |
Jeff Hung | Morgan Stanley |
Yatin Suneja | Guggenheim |
Good day, ladies and gentlemen. Thank you for standing by. Welcome to ACADIA Pharmaceuticals’ First Quarter 2023 Financial Results Conference Call. My name is Corey and I'll be your coordinator for today. At this time, all participants are in a listen-only mode.